CN100384469C - 肺病治疗药物 - Google Patents

肺病治疗药物 Download PDF

Info

Publication number
CN100384469C
CN100384469C CNB03807463XA CN03807463A CN100384469C CN 100384469 C CN100384469 C CN 100384469C CN B03807463X A CNB03807463X A CN B03807463XA CN 03807463 A CN03807463 A CN 03807463A CN 100384469 C CN100384469 C CN 100384469C
Authority
CN
China
Prior art keywords
purposes
atiii
antithrombin iii
lung
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03807463XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1774258A (zh
Inventor
村上和宪
P·恩克巴塔
L·D·特拉伯
D·S·普劳格
D·N·赫恩顿
D·L·特拉伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas at Austin
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of CN1774258A publication Critical patent/CN1774258A/zh
Application granted granted Critical
Publication of CN100384469C publication Critical patent/CN100384469C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB03807463XA 2002-04-01 2003-03-25 肺病治疗药物 Expired - Fee Related CN100384469C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36899702P 2002-04-01 2002-04-01
US60/368,997 2002-04-01

Publications (2)

Publication Number Publication Date
CN1774258A CN1774258A (zh) 2006-05-17
CN100384469C true CN100384469C (zh) 2008-04-30

Family

ID=29420316

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03807463XA Expired - Fee Related CN100384469C (zh) 2002-04-01 2003-03-25 肺病治疗药物

Country Status (10)

Country Link
US (1) US20090221475A9 (https=)
EP (1) EP1494696A4 (https=)
JP (2) JP2005527570A (https=)
KR (2) KR20100117148A (https=)
CN (1) CN100384469C (https=)
AU (3) AU2003233428B2 (https=)
CA (1) CA2480790A1 (https=)
IL (2) IL164078A0 (https=)
NZ (1) NZ535487A (https=)
WO (1) WO2003084476A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US8753882B2 (en) 2010-10-12 2014-06-17 Vetgel Technologies Methods and compositions for treating respiratory conditions using platelet enriched plasma
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
CN113905724A (zh) * 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
US20240050525A1 (en) * 2021-02-17 2024-02-15 University Of Rochester Methods of treating, diagnosing and predicting prognosis of sepsis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021332A1 (de) * 1991-05-25 1992-12-10 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08782B2 (ja) * 1986-11-22 1996-01-10 株式会社ミドリ十字 抗炎症剤
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
WO2000023569A1 (en) * 1998-10-20 2000-04-27 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021332A1 (de) * 1991-05-25 1992-12-10 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment

Also Published As

Publication number Publication date
JP2011225625A (ja) 2011-11-10
KR20100117148A (ko) 2010-11-02
CN1774258A (zh) 2006-05-17
KR20040105838A (ko) 2004-12-16
WO2003084476A2 (en) 2003-10-16
EP1494696A2 (en) 2005-01-12
NZ535487A (en) 2008-12-24
AU2011236070A1 (en) 2011-11-03
CA2480790A1 (en) 2003-10-16
AU2003233428A1 (en) 2003-10-20
WO2003084476A3 (en) 2004-04-22
IL164078A (en) 2011-02-28
IL164078A0 (en) 2005-12-18
AU2008243077A1 (en) 2008-11-27
US20090221475A9 (en) 2009-09-03
JP2005527570A (ja) 2005-09-15
EP1494696A4 (en) 2006-01-25
US20040192595A1 (en) 2004-09-30
AU2003233428B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP2011225625A (ja) 肺障害の治療
Leversha et al. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma
TWI417108B (zh) 於肺內區中以半氟化烷類作為活性物質載體的吸入式及滴入式使用
AU2011295165B2 (en) Humidified particles comprising a therapeutically active substance
AU657726B2 (en) Devices for treating pulmonary vasoconstriction and asthma
KR100910888B1 (ko) 에어로졸화 이송을 위한 적절한 토브라마이싱의 조성물
ES2792682T3 (es) Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
EP0502054B1 (en) An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
JPH03501852A (ja) エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法
AU2021326382B2 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
HK1087930A (en) Treatment of lung disorder
US20220064328A1 (en) Formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalation
WO2022118220A1 (en) Compositions, devices, and methods for treating respiratory disorders
Ibrahim et al. Inhaled Therapy for Other Respiratory Diseases: Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis
Saeed et al. Stability of commonly nebulized drugs in heated and humid condition
Challoner Aerosol delivery of antibiotics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087930

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: UNIV. TEXAS

Free format text: FORMER OWNER: GTC BIOTHERAPEUTIC CORP.

Effective date: 20110422

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: MASSACHUSETTS, THE USA TO: TEXAS, THE USA

TR01 Transfer of patent right

Effective date of registration: 20110422

Address after: Texas in the United States

Patentee after: Univ. Texas

Address before: Massachusetts, USA

Patentee before: GTC Biotherapeutic Corp.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1087930

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080430

Termination date: 20120325